基于常规超声的慢性肾病纤维化评估新诊断工具的开发与部署
本研究前瞻性纳入162例接受肾活检和超声检查的慢性肾病患者,随机分为训练组114例和验证组48例,开发了名为S-CKD的超声计算机辅助诊断工具,用于区分轻度和中重度肾纤维化。S-CKD在训练组和验证组的AUC分别为0.84和0.81,校准良好,决策曲线分析显示具有较高临床价值。
要点
- S-CKD工具基于常规超声特征和人口学变量,可区分轻度和中重度肾纤维化。
- 训练组AUC为0.84,验证组AUC为0.81,校准曲线显示预测准确性良好。
- 该工具已部署为在线网页和离线文档两种易用形式,辅助临床决策。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Accurate identification of risk information about fibrosis severity is crucial for clinical decision-making and clinical management of patients with chronic kidney disease (CKD). This study aimed to develop an ultrasound (US)-derived computer-aided diagnosis tool for identifying CKD patients at high risk of developing moderate-severe renal fibrosis, in order to optimize treatment regimens and follow-up strategies.
MATERIALS AND METHODS: A total of 162 CKD patients undergoing renal biopsies and US examinations were prospectively enrolled and randomly divided into training (n = 114) and validation (n = 48) cohorts. A multivariate logistic regression approach was employed to develop the diagnostic tool named S-CKD for differentiating moderate-severe renal fibrosis from mild one in the training cohort by integrating the significant variables, which were screened out from demographic characteristics and conventional US features via the least absolute shrinkage and selection operator regression algorithm. The S-CKD was then deployed as both an online web-based and an offline document-based, easy-to-use auxiliary device. In both the training and validation cohorts, the S-CKD's diagnostic performance was evaluated through discrimination and calibration. The clinical benefit of using S-CKD was revealed by decision curve analysis (DCA) and clinical impact curves.
RESULTS: The proposed S-CKD achieved an area under the receiver operating characteristic curve of 0.84 (95% confidence interval (CI): 0.77-0.91) and 0.81 (95% CI: 0.68-0.94) in the training and validation cohorts, respectively, indicating satisfactory diagnosis performance. Results of the calibration curves showed that S-CKD has excellent predictive accuracy (Hosmer-Lemeshow test: training cohort, p = 0.497; validation cohort, p = 0.205). The DCA and clinical impact curves exhibited a high clinical application value of the S-CKD at a wide range of risk probabilities.
CONCLUSION: The S-CKD tool developed in this study is capable of discriminating between mild and moderate-severe renal fibrosis in patients with CKD and achieving promising clinical benefits, which may aid clinicians in personalizing medical decision-making and follow-up arrangement.
引用
- Chen, Chen, Ying, et al. Development and Deployment of a Novel Diagnostic Tool Based on Conventional Ultrasound for Fibrosis Assessment in Chronic Kidney Disease. Acad Radiol. 2023. PMID: 36973117. doi:10.1016/j.acra.2023.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。